See every side of every news story

Published 5 days ago • loading... • Updated 5 days ago

Helus Pharma Completes Enrollment in Phase 3 APPROACH Study of HLP003 in Adjunctive Treatment of Major Depressive Disorder Ahead of Schedule

Summary by Financial Post

Enrollment continues in EMBRACE, the second pivotal study of the Phase 3 PARADIGM Program Participant rollover is ongoing into the EXTEND long-term study generating long-term safety and durability data APPROACH topline data readout on track for Q4 20261,2 HLP003 previously granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration (“FDA”) HLP003 Phase 2 […]

3 Articles

3 Articles

The Hamilton Spectator

+2 Reposted by 2 other sources

Helus Pharma Completes Enrollment in Phase 3 APPROACH Study of HLP003 in Adjunctive Treatment of Major Depressive Disorder Ahead of Schedule

Enrollment continues in EMBRACE, the second pivotal study of the Phase 3 PARADIGM Program

6 days ago·Hamilton, Canada

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Coverage Details

Total News Sources3

Leaning Left1Leaning Right1Center0Last Updated5 days agoBias Distribution

50% Left, 50% Right

Bias Distribution

50% of the sources lean Left, 50% of the sources lean Right

50% Right

Untracked bias

Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

The Hamilton Spectator broke the news in Hamilton, Canada 6 days ago on Tuesday, July 21, 2026.

Sources are mostly out of (0)

Similar News Topics

Similar News Topics